The Sales & Marketing Effectiveness in Chemicals Forum will bring together industry leaders as well as experts responsible and deeply involved in sales and marketing strategies.
LatAm market rising in the eyes of pharmaceutical companies
Latin America is one of the emerging regions for the pharmaceutical industry. What are the top 5 reasons?
1. It is a fast-growing region, with fast-growing economies
According to Pharmtech, by mid-2016, the number of inhabitants in Latin America will rise to 625 million, more than six million above the estimated total population in mid-2015.
The leading countries according to VisionGain's report are Brazil, Mexico, Venezuela, Argentina, Colombia and Chile. Among the leading companies are Sanofi, EMS, Novartis, Pfizer and Bayer. Representatives from three of them are currently among our speakers.
2. Innovation, affordability and availability
Facilitation of market access is possible mainly because of the Agreement for Innovation, introduced in the second half of 2012. Companies in Latin America do a lot to work with governments and make sure innovation is available. Plus, about 78% of all medicines are paid for out-of-pocket in retail pharmacies.
3. The crisis did not have such an impact here
After the crisis, more restrictions and protectionist measures were generally imposed or enhanced, which had a negative impact for multinational companies. As pharma regulatory affairs consultant María Inés Guaia says, LatAm countries are pretty inelastic: a significant share of the pharma market is managed by national health authorities and social health insurance companies that didn't significantly cut expenditure in healthcare due to the crisis.
4. The trend towards standardized regulations is increasing
While each of the previously mentioned six major markets has adopted regulations that are based on Mercosur or PAHO recommendations, international health institutes and agencies like COFERPRIS are also pushing countries towards authorizations, certification and better consistency across countries.
5. Clinical trials and R&D
Currently, an estimated 4,000 clinical trials are being conducted. Discover the future of compliance in this rising market.
Be part of the event!
2nd Annual Pharmaceutical Compliance in Latin America Congress
Interested in this topic?
12th Project & Portfolio Management in the Pharmaceutical Industry Congress
12th Project and Portfolio Management Congress in Europe presents a high-level meeting looking at the best ways forward in enhanced R&D productivity, forecasting and ultimately, optimizing balance throughout the lifecycle.
Pharmaceutical Cold Chain & Logistics in Latin America
Join professionals from Latin America in a remarkable event that will be a step ahead in your professional career thanks the ultimate knowledge and insights shared in these two days.
5th Annual Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform to discuss compliance and transparency areas of key concern. Goal is to unravel compliance challenges, define and learn fair market value and develop a consistent, simple and transparent method and strategy for your company.
Interview: A holistic approach to the strategic planning process
Read the full interview with Ken Dobie, Founder & Principal of Skyemar Consulting, Former Director, Corporate Planning & Portfolio Management, Illumina and gain the insight into the aligning strategic priorities to portfolio management and associated resources.
Interview: East vs. West – Is there a regional approach to PPM in the US?
Read the full interview with Leigh Shultz, PhD, PMP, Associate Vice President, Project Management – Primary Care, Infectious Disease, Vaccines, Global Project & Alliance Management, Merck and gain insight into the regional approach to PPM across the US.
Interview: Project & Portfolio Management for Pharma & Biotech
Read the full interview with Eric Towler, Therapeutic Area Lead, BioPharma Project Management, Bristol-Myers Squibb and gain insight into the latest PPM trends.